A Study of Debio 1347 Plus Fulvestrant in Patients With Metastatic Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: Fulvestrant|DRUG: Debio 1347
Sponsor: Memorial Sloan Kettering Cancer Center
Collaborators: Debiopharm International SA